| Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus TAS Halden, KE Kvitne, K Midtvedt, L Rajakumar, I Robertsen, J Brox, ... Diabetes care 42 (6), 1067-1074, 2019 | 174 | 2019 |
| Short‐and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity–a non‐randomized three‐armed controlled trial KE Kvitne, I Robertsen, E Skovlund, H Christensen, V Krogstad, C Wegler, ... Clinical and Translational Science 15 (1), 221-233, 2022 | 20 | 2022 |
| Short‐and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity KE Kvitne, V Krogstad, C Wegler, LK Johnson, MK Kringen, MH Hovd, ... British Journal of Clinical Pharmacology 88 (9), 4121-4133, 2022 | 19 | 2022 |
| Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body … K Eide Kvitne, K Hole, V Krogstad, BM Wollmann, C Wegler, LK Johnson, ... European journal of clinical pharmacology 78 (8), 1289-1299, 2022 | 14 | 2022 |
| Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity KE Kvitne, A Åsberg, LK Johnson, C Wegler, JK Hertel, P Artursson, ... Clinical and Translational Science 15 (11), 2685-2696, 2022 | 8 | 2022 |
| Intraindividual variability in absolute bioavailability and clearance of midazolam in healthy individuals KE Kvitne, OM Drevland, N Haugli, E Skadberg, HK Zaré, A Åsberg, ... Clinical Pharmacokinetics 62 (7), 981-987, 2023 | 5 | 2023 |
| Neither gastric bypass surgery nor diet-induced weight-loss affect OATP1B1 activity as measured by rosuvastatin oral clearance M Hovd, I Robertsen, LK Johnson, V Krogstad, C Wegler, KE Kvitne, ... Clinical Pharmacokinetics 62 (5), 725-735, 2023 | 2 | 2023 |
| Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon V Arya, JD Ma, KE Kvitne Pharmaceutics 16 (7), 855, 2024 | 1 | 2024 |
| Oral Drug Dosing After Gastric Bypass and Diet‐Induced Weight Loss: Simpler Than We Think? Lessons Learned From the COCKTAIL Study KE Kvitne, J Hjelmesæth, M Hovd, R Sandbu, LK Johnson, S Andersson, ... Clinical Pharmacology & Therapeutics, 2024 | 1 | 2024 |
| Digoxin pharmacokinetics in patients with obesity before and after a gastric bypass or a strict diet compared with normal weight individuals KE Kvitne, M Hovd, LK Johnson, C Wegler, C Karlsson, P Artursson, ... Clinical Pharmacokinetics 63 (1), 109-120, 2024 | 1 | 2024 |
| Response to:“Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time” KE Kvitne, K Hole, E Molden, I Robertsen European Journal of Clinical Pharmacology 78 (11), 1865-1866, 2022 | 1 | 2022 |
| Pharmacokinetic variability in patients with obesity and healthy individuals–the role of cytochrome P450 KE Kvitne | 1 | 2022 |
Ida RobertsenAssociate professor, University of Oslo在 farmasi.uio.no 的电子邮件经过验证
